Oregon Health & Science University Background
CD74 interactions with migration inhibitory factor (MIF) is a growing area of cancer and immunology research. However, current recombinant versions of CD74 have a limited ability to bind MIF.
Researchers at OHSU have developed an E. coli-expressed recombinant version of human CD74 with the following properties:
Improved binding of MIF-1 and MIF-2, as compared to commercially available versions of recombinant CD74.
Demonstrated ability to bind several antibodies currently used in human CD74 biology research and recombinant human and mouse Class II proteins.
Stable, with no decrease in activity, when stored at -80 °C in glycerol for up to 6 months.
Meza-Romero et al., “Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.” Metabolic Brain Disease 2019. Link
Benedek et al., “MIF and D-DT are potential disease severity modifiers in male MS subjects.” PNAS 2017. Link
Currently available versions of recombinant CD74 have a limited ability to bind MIF; however, this version has a demonstrated ability to bind MIF‑1 and MIF‑2.
This recombinant protein could be utilized for cancer and immunology research exploring the CD74‑MIF axis.
This technology is available for licensing.